The purpose of this study is to test if the experimental treatment of a combination of sacituzumab govitecan and pembrolizumab can improve outcomes and delay the return of disease in participants with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.
Learn more about the ASCENT-5 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
